Buy 1cP-MiPLA for sale online from USA vendor

Table of Contents

1. Introduction

   • 1.1 Overview of 1-Cyclopropionyl-N-methyl-N-isopropyllysergamide (1cP-MiPLA)
   • 1.2 Emergence and Synthesis
   • 1.3 User Reports and Effects

2. Chemistry

   • 2.1 Chemical Structure of 1cP-MiPLA
   • 2.2 Dosage Guidelines
   • 2.3 Pharmacological Properties

3. Physical Effects

   • 3.1 Stimulation
   • 3.2 Spontaneous Bodily Sensations
   • 3.3 Physical Euphoria
   • 3.4 Changes in Felt Bodily Form
   • 3.5 Tactile Enhancement
   • 3.6 Temperature Regulation
   • 3.7 Stamina Enhancement
   • 3.8 Bodily Control Enhancement
   • 3.9 Other Physical Effects

4. Visual Effects

   • 4.1 Enhancements
   • 4.2 Distortions
   • 4.3 Geometry
   • 4.4 Hallucinatory States

5. Combination Effects

   • 5.1 Alcohol
   • 5.2 Benzodiazepines
   • 5.3 Cannabis
   • 5.4 Dissociatives
   • 5.5 MDMA

6. Toxicity and Harm Potential

   • 6.1 General Considerations
   • 6.2 Health Effects
   • 6.3 Psychiatric Considerations

7. Dependence, Abuse Potential, and Overdose

   • 7.1 Dependence and Tolerance
   • 7.2 Overdose

8. Dangerous Interactions

   • 8.1 General Warning
   • 8.2 Specific Interactions

9. Legal Status

   • 9.1 Global Overview
   • 9.2 Country-Specific Status

Introduction

1-Cyclopropionyl-N-methyl-N-isopropyllysergamide, commonly known as 1cP-MiPLA, is a recently discovered psychedelic substance belonging to the lysergamide class. It shares close ties with MiPLA, hinting at a potential prodrug relationship, though current data and anecdotal reports lack sufficient evidence to firmly support this hypothesis.

Emergence and Synthesis

First emerging in 2020 or 2021, 1cP-MiPLA is attributed to either Skyler Ulrich or a chemist/group using the name Gerstmann, alongside other lysergamides like 1cP-AL-LAD, finding its way into various research chemical markets.

User Reports and Effects

User reports describe 1cP-MiPLA effects as similar to MiPLA, with some noting potential subtle differences. Despite this, it remains unclear whether 1cP-MiPLA is a true prodrug for MiPLA. Caution is advised due to limited data on its pharmacological properties, metabolism, and toxicity, even though users generally characterize it as more recreational and less threatening than LSD.

Chemistry

1cP-MiPLA is a semisynthetic lysergamide with a complex chemical structure. It features a bicyclic hexahydroindole fused to a bicyclic quinoline group, with a Cyclopropionyl substituent at R1 and an N,N-diethyl carboxamide at carbon 8 of the quinoline. The compound is chiral, having two stereocenters at R5 and R8.

Dosage Guidelines

Understanding the dosage is crucial when dealing with potent substances like 1cP-MiPLA. Threshold, light, common, strong, and heavy dosages are identified as 50 µg, 100-150 µg, 150-200 µg, 200-250 µg, and 300 µg and above, respectively.

Pharmacology

1cP-MiPLA is believed to act as a 5-HT2A partial agonist, inducing psychedelic effects through interactions with these receptors. It is also suspected to be a prodrug for MiPLA, akin to 1cP-LSD and LSD. However, the lack of sufficient data prevents certainty in this regard.

Subjective Effects

Subjective effects of 1cP-MiPLA overlap with those of MiPLA and, to a lesser extent, LSD. Notably, 1cP-MiPLA is reported to have a shorter duration and is less uncomfortable in terms of negative physical side effects and general anxiety compared to its counterparts.

Disclaimer

It's crucial to approach 1cP-MiPLA with caution, as the information provided is based on subjective reports and the SEI (Subjective Effect Index). Effects may vary unpredictably, and higher doses can lead to increased risks, including addiction, severe injury, or death.

Physical Effects

Similar to LSD, 1cP-MiPLA is predominantly stimulating, distinguishing it from other commonly used psychedelics like psilocybin, which tend to induce sedation and relaxedness.

Spontaneous Bodily Sensations

The "body high" of 1cP-MiPLA is described as intensely proportionate to its visual and cognitive effects. It presents as a pleasurable, fast-moving, sharp, and location-specific tingling sensation. While slightly less sharp than LSD, it remains essentially indistinguishable. The sensation can manifest spontaneously or steadily rise with the onset, reaching its peak during the experience.

Physical Euphoria

Physical euphoria on 1cP-MiPLA varies and may manifest as discomfort without apparent reason. It lacks the consistency seen with stimulants or entactogens.

Changes in Felt Bodily Form

Accompanied by warmth or unity, changes in felt bodily form occur during and up to the peak of the experience. Users may feel physically connected or conjoined with other objects, reporting comfortable and peaceful sensations.

Tactile Enhancement

Enhanced tactile sensations are consistently present at moderate levels throughout most 1cP-MiPLA trips.

Temperature Regulation

1cP-MiPLA induces temperature regulation suppression, increased bodily temperature, and occasionally nausea.

Stamina Enhancement

Stamina enhancement is generally mild compared to traditional stimulants.

Bodily Control Enhancement

Users may experience enhanced bodily control, along with appetite suppression and difficulty urinating.

Cardiovascular Effects

1cP-MiPLA is associated with increased blood pressure, heart rate, perspiration, muscle contractions, muscle spasms, and increased libido.

Miscellaneous Effects

Excessive yawning, pupil dilation, increased salivation, and a risk of seizures (particularly in genetically predisposed individuals under physically taxing conditions) are reported effects.

Visual Effects

Enhancements

1cP-MiPLA induces various visual enhancements, including heightened visual acuity, intensified colors, and enhanced pattern recognition.

Distortions

Drifting

Described as highly detailed yet cartoon-like, the drifting effect of 1cP-MiPLA is slow, smooth, and fleeting—resembling the visual drifting experienced under LSD.

After Images, Tracers, and Color Shifting

After images, tracers, and color shifting contribute to the complexity of visual distortions induced by 1cP-MiPLA.

Depth Perception Distortions, Diffraction, Scenery Slicing, Symmetrical Texture Repetition

Additional distortions include depth perception alterations, diffraction, scenery slicing, and symmetrical texture repetition, enhancing the visual experience.

Geometry

1cP-MiPLA's visual geometry aligns more with LSD, 2C-B, or 4-HO-MET than psilocin, LSA, or DMT. It is intricate, algorithmic, unstructured, brightly lit, colorful, cartoonish, organic, flat-shaded, soft-edged, large, slow, smooth, and non-immersive. Higher dosages result in Level 8B visual geometry.

In comparison to LSD, 1cP-MiPLA's geometry features rounded corners, softer edges, warmer hues, and slightly less intricate forms while maintaining an overall identical appearance.

Hallucinatory States

1cP-MiPLA can induce a range of hallucinatory states, less consistent than psilocin or DMT but more likely than LSD. Effects include machinescapes, transformations, and internal hallucinations with consistent believability, interactivity, novelty, autonomy, and geometry-based styles.

Cognitive Effects

Analysis Enhancement, Conceptual Thinking, Cognitive Euphoria

1cP-MiPLA consistently enhances analysis, conceptual thinking, and induces cognitive euphoria.

Novelty Enhancement, Immersion Enhancement, Focus Enhancement

Novelty and immersion enhancement, along with focus enhancement, are reported effects, with the latter occurring at lower or threshold dosages.

Motivation Enhancement, Emotion Enhancement, Increased Music Appreciation

Motivation enhancement, emotion enhancement, and heightened music appreciation contribute to the cognitive experience.

Increased Sense of Humor, Laughter Fits

Users may experience an increased sense of humor and laughter fits, adding a lighthearted aspect to the cognitive effects.

Memory Suppression, Ego Death, Time Distortion

Memory suppression, ego death, and time distortion are notable cognitive alterations induced by 1cP-MiPLA.

Déjà Vu, Delusion, Thought Acceleration, Thought Loops, Wakefulness

Other cognitive effects include déjà vu, delusion, thought acceleration, thought loops, and wakefulness.

Auditory Effects

Auditory Distortion, Auditory Enhancement, Auditory Hallucination

Auditory effects encompass distortion, enhancement, and occasional hallucination, contributing to the multisensory experience.

Transpersonal Effects

Transpersonal effects, such as existential self-realization, unity, and interconnectedness, are reported to be weaker in comparison to LSD and other classical psychedelics like psilocybin mushrooms or mescaline.

Combination Effects

Alcohol

While alcohol's central depressant effects may counteract anxiety and bodily tension induced by 1cP-MiPLA, caution is advised due to potential dehydration, nausea, and physical fatigue. Users are urged to pace themselves and consume a fraction of their usual alcohol amount.

Benzodiazepines

Benzodiazepines effectively reduce the intensity of 1cP-MiPLA's effects by suppressing brain activity. Users can use benzodiazepines to manage the experience.

Cannabis

Combining cannabis with 1cP-MiPLA intensifies sensory and cognitive effects. Extreme caution is recommended to avoid negative psychological reactions like anxiety and psychosis. Users should start with a fraction of their usual cannabis dose and take long breaks between hits.

Dissociatives

1cP-MiPLA enhances the effects of dissociatives, intensifying cognitive, visual, and hallucinatory experiences. However, this also increases the risk of confusion, delusions, and psychosis.

MDMA

1cP-MiPLA and MDMA exhibit high synergy, enhancing physical, cognitive, and visual effects. Users should start with lower doses than usual due to the unpredictable nature of this combination.

Toxicity and Harm Potential

General Considerations

The toxicity and long-term health effects of 1cP-MiPLA remain largely unstudied, given its status as a research chemical with limited human usage history.

Health Effects

Anecdotal reports suggest no negative health effects with low to moderate doses. However, users are advised to conduct independent research before combining substances to ensure safety.

Psychiatric Considerations

1cP-MiPLA may act as a trigger for individuals with underlying psychiatric conditions. Those with a personal or family history of mental illness are advised against its use, especially outside supervised medical settings.

Dependence, Abuse Potential, and Overdose

Dependence and Tolerance

No formal studies exist, but it is presumed that, like LSD, 1cP-MiPLA is non-habit-forming. Tolerance builds almost immediately, with a reduction to half after 5-7 days and a return to baseline after 14 days.

Overdose

The LD50 of 1cP-MiPLA is unknown. Adverse psychological reactions, such as anxiety and delusions, are common at higher doses. Medical attention may be needed in severe cases or if other substances, like "fake acid," are suspected. Benzodiazepines or antipsychotics can alleviate negative cognitive effects.

Dangerous Interactions

General Warning

Combining substances can be dangerous. Independent research is crucial to ensure safety.

Specific Interactions

Lithium

Combining lithium with psychedelics, including 1cP-MiPLA, may increase the risk of psychosis and seizures, strongly discouraged.

Cannabis

Caution is advised when combining cannabis with 1cP-MiPLA due to an unpredictable synergy, potentially leading to adverse psychological reactions.

Stimulants

Combining stimulants with 1cP-MiPLA increases the risk of anxiety, paranoia, panic attacks, and thought loops. Elevated risk of mania and psychosis may also occur.

Tramadol

Tramadol, known for lowering the seizure threshold, combined with psychedelics may trigger seizures in susceptible individuals.

Legal Status

Global Overview

1cP-MiPLA exists in a legal gray area in many parts of the world, with legality varying by country.

Country-Specific Status

Austria

Not explicitly illegal, but may be subject to analog laws.

Germany

Illegal as of July 2021.

Switzerland

Considered a controlled substance but legal for scientific or industrial use.

United States

Unscheduled but may be considered an analogue of LSD, making it illegal for human consumption under the Federal Analogue Act.

FAQ (Frequently Asked Questions)

Q1: What is 1cP-MiPLA?

1cP-MiPLA is a novel lysergamide, closely related to MiPLA, and emerged in research chemical markets around 2020 or 2021.

Q2: How does 1cP-MiPLA compare to LSD and MiPLA?

User reports suggest similarities to MiPLA and LSD, with some noting subtle differences. It is suspected to be a prodrug for MiPLA, but more research is needed.

Q3: What are the recommended dosages for 1cP-MiPLA?

Dosages range from 50 µg (threshold) to 300 µg and above (heavy). It is crucial to follow guidelines for harm reduction.

Q4: What are the potential visual effects of 1cP-MiPLA?

Visual effects include enhancements, distortions, unique geometry, and hallucinatory states. The experience is often compared to LSD.

Q5: Can 1cP-MiPLA be combined with other substances?

Combining with substances like alcohol, benzodiazepines, cannabis, dissociatives, and MDMA is possible, but caution is strongly advised due to unpredictable effects.

Q6: Is 1cP-MiPLA addictive?

There is no evidence to suggest that 1cP-MiPLA is addictive. Tolerance builds almost immediately, and desire to use may decrease with continued use.

Q7: What is the legal status of 1cP-MiPLA?

Legal status varies by country. It is considered a gray area compound in many parts of the world, but some countries, such as Germany, have classified it as illegal. Always check local regulations.

Q8: Are there dangerous interactions with 1cP-MiPLA?

Yes, interactions with substances like lithium, cannabis, and stimulants can be dangerous. Independent research is crucial to ensure safety.

Q9: Is there a risk of overdose with 1cP-MiPLA?

The LD50 is unknown, and adverse psychological reactions are common at higher doses. Medical attention may be needed in severe cases, and benzodiazepines can help alleviate negative effects.

Q10: Should individuals with mental health conditions use 1cP-MiPLA?

Individuals with underlying psychiatric conditions, personal or family history of mental illness, are generally advised against using 1cP-MiPLA, especially without supervision.

Q11: How should users approach harm reduction with 1cP-MiPLA?

It is strongly recommended to practice harm reduction by researching interactions, starting with low doses, and ensuring a safe environment.